March 18, 2019
When it comes to selecting a biologic to treat psoriasis, patient response and patient-reported outcomes weigh heavily in treatment decisions, according to a study published online in the Journal of the American Academy of Dermatology.
“Psoriasis Area and Severity Index (PASI) is most important for dermatologists selecting biologics, but patient-reported outcomes are also considered, especially when PASI response rate is similar between treatments,” researchers wrote. “Patient-reported outcomes data should be collected in moderate-to severe-psoriasis trials.”
The study was based on a pair of online surveys that included a total 259 US dermatologists. Respondents were asked to select hypothetical biologics based on six attributes: PASI 75 or 90 response rate, infection risk, dosing frequency, and three patient-reported outcomes (relief of depression and itching, and impact on usual activities).
About three-quarters of dermatologists reported using both PASI and patient-reported outcomes when selecting a biologic, researchers found. The PASI response rate garnered between 35% and 38% of dermatologists’ overall decision weight. Patient-reported outcomes drew 36% of decision weight.
Infection risk and dosing frequency also influenced treatment decisions, but to a lesser extent, researchers reported.
Feldman SR, Regnier SA, Chirilov A, Hey F, Gilloteau I, Cella D. Patient-reported outcomes are important elements of psoriasis treatment decision making: a discrete choice experiment survey of dermatologists in the United States [published online January 28, 2019]. J Am Acad Dermatol.